Eagle Global Advisors’s AbbVie ABBV Stock Holding History

Eagle Global Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$19.9M	Sell	79,227 -422	-0.5%	-$90.8K	0.66%	41
2026 Q1	$17.3M	Buy	79,649 +25	+0%	+$5.55K	0.62%	43
2025 Q4	$18.2M	Buy	79,624 +158	+0.2%	+$36K	0.67%	39
2025 Q3	$18.4M	Sell	79,466 -645	-0.8%	-$131K	0.71%	34
2025 Q2	$14.9M	Sell	80,111 -665	-0.8%	-$124K	0.6%	38
2025 Q1	$16.9M	Sell	80,776 -546	-0.7%	-$106K	0.7%	33
2024 Q4	$14.5M	Buy	81,322 +14,800	+22%	+$2.72M	0.59%	38
2024 Q3	$13.1M	Sell	66,522 -830	-1%	-$155K	0.65%	37
2024 Q2	$11.6M	Buy	67,352 +771	+1%	+$128K	0.61%	41
2024 Q1	$12.1M	Buy	66,581 +63,284	+1,919%	+$10.9M	0.68%	42
2023 Q4	$511K	Buy	3,297 +463	+16%	+$67.5K	0.03%	168
2023 Q3	$422K	Hold	2,834	–	–	0.03%	175
2023 Q2	$382K	Buy	2,834 +200	+8%	+$29.3K	0.03%	180
2023 Q1	$420K	Hold	2,634	–	–	0.03%	174
2022 Q4	$426K	Buy	2,634 +100	+4%	+$15.3K	0.03%	167
2022 Q3	$340K	Buy	2,534 +275	+12%	+$39.5K	0.03%	181
2022 Q2	$346K	Hold	2,259	–	–	0.03%	179
2022 Q1	$366K	Hold	2,259	–	–	0.02%	195
2021 Q4	$306K	Hold	2,259	–	–	0.02%	203
2021 Q3	$244K	Hold	2,259	–	–	0.02%	217
2021 Q2	$254K	Hold	2,259	–	–	0.02%	223
2021 Q1	$244K	Hold	2,259	–	–	0.02%	229
2020 Q4	$242K	Sell	2,259 -600	-21%	-$57.7K	0.02%	196
2020 Q3	$250K	Sell	2,859 -400	-12%	-$37.7K	0.02%	180
2020 Q2	$320K	Sell	3,259 -66	-2%	-$5.81K	0.03%	163
2020 Q1	$253K	Sell	3,325 -187	-5%	-$15.9K	0.03%	165
2019 Q4	$311K	Sell	3,512 -100	-3%	-$8.3K	0.02%	188
2019 Q3	$274K	Sell	3,612 -1,175	-25%	-$80.6K	0.01%	189
2019 Q2	$348K	Buy	4,787 +50	+1%	+$3.93K	0.01%	189
2019 Q1	$382K	Sell	4,737 -1,100	-19%	-$90K	0.01%	177
2018 Q4	$538K	Sell	5,837 -1,500	-20%	-$132K	0.02%	163
2018 Q3	$694K	Sell	7,337 -2,000	-21%	-$190K	0.02%	161
2018 Q2	$865K	Hold	9,337	–	–	0.03%	150
2018 Q1	$884K	Sell	9,337 -1,213	-11%	-$133K	0.03%	154
2017 Q4	$1.02M	Buy	10,550 +100	+1%	+$9.43K	0.03%	146
2017 Q3	$929K	Sell	10,450 -3,028	-22%	-$231K	0.03%	150
2017 Q2	$977K	Buy	13,478 +2,433	+22%	+$164K	0.03%	151
2017 Q1	$720K	Buy	11,045 +3,495	+46%	+$220K	0.02%	177
2016 Q4	$473K	Hold	7,550	–	–	0.01%	219
2016 Q3	$476K	Hold	7,550	–	–	0.01%	214
2016 Q2	$467K	Buy	7,550 +825	+12%	+$50.3K	0.01%	206
2016 Q1	$384K	Hold	6,725	–	–	0.01%	234
2015 Q4	$398K	Sell	6,725 -500	-7%	-$28.8K	0.01%	235
2015 Q3	$393K	Hold	7,225	–	–	0.01%	236
2015 Q2	$485K	Sell	7,225 -472	-6%	-$30.8K	0.01%	217
2015 Q1	$451K	Buy	7,697 +472	+7%	+$28.5K	0.01%	201
2014 Q4	$473K	Sell	7,225 -125	-2%	-$7.88K	0.01%	201
2014 Q3	$425K	Hold	7,350	–	–	0.01%	198
2014 Q2	$415K	Hold	7,350	–	–	0.01%	187
2014 Q1	$378K	Sell	7,350 -50	-0.7%	-$2.53K	0.01%	185
2013 Q4	$391K	Hold	7,400	–	–	0.01%	181
2013 Q3	$331K	Hold	7,400	–	–	0.01%	189
2013 Q2	$306K	Buy	+7,400	New	+$324K	0.01%	184

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Eagle Global Advisors's ABBV Position: Q2 2026 in Review

Eagle Global Advisors reduced its AbbVie (ABBV) stake by 0.53% in Q2 2026, selling an estimated $90.8K and leaving 79,227 shares worth $19.9M. The position accounts for 0.66% of the portfolio, ranked #41.

Eagle Global Advisors first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. 4,189 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Eagle Global Advisors held 79,227 shares of AbbVie worth $19.9M as of Q2 2026.
Eagle Global Advisors sold 422 AbbVie shares in Q2 2026, an estimated $90.8K.
AbbVie made up 0.66% of Eagle Global Advisors's portfolio in Q2 2026, its #41 holding.
Eagle Global Advisors first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
4,189 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Eagle Global Advisors's 13F filing for Q2 2026, filed 30 Jul 2026.